Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 13/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14940959 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14941016 | 0.92 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14941018 | 0.92 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14941383 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14941382 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL16194964 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14952141 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14941167 | 0.84 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14952145 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL16194908 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776423-B1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2776423-B1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9994548-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994548-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994548-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170107197-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-20170107197-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-20170107197-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-9346784-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346784-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346784-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140323461-A1 | Phenyl-Substituted Nicotinic Ligands, and Methods of Use Thereof | DUKE UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| US-20140323461-A1 | Phenyl-Substituted Nicotinic Ligands, and Methods of Use Thereof | DUKE UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| US-20140323461-A1 | Phenyl-Substituted Nicotinic Ligands, and Methods of Use Thereof | DUKE UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| EP-2776423-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | Georgetown University (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071067-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071067-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107197-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | PSEN1, PNMT, OPRL1 | CHRNB2 56/4885CHRNA4 12/4885CHRNB4 36/4885 |
| US-20140323461-A1 | Phenyl-Substituted Nicotinic Ligands, and Methods of Use Thereof | PSEN1, PNMT, OPRL1 | CHRNB2 56/4885CHRNA4 12/4885CHRNB4 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.